Last reviewed · How we verify

Glycopyrronium/Formoterol Fumarate

AstraZeneca · Phase 3 active Small molecule

Glycopyrronium/Formoterol Fumarate is a LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Glycopyrronium is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and improve bronchial tone, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle to improve airflow.

Glycopyrronium is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and improve bronchial tone, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle to improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameGlycopyrronium/Formoterol Fumarate
SponsorAstraZeneca
Drug classLAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist)
TargetMuscarinic M3 receptor; Beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

This combination inhaler delivers two complementary bronchodilators: glycopyrronium (a long-acting muscarinic antagonist or LAMA) blocks parasympathetic signaling to reduce bronchoconstriction and mucus production, while formoterol (a long-acting beta-2 agonist or LABA) activates beta-2 adrenergic receptors on airway smooth muscle to promote relaxation and bronchodilation. Together, they provide dual-mechanism airway opening for sustained symptom relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glycopyrronium/Formoterol Fumarate

What is Glycopyrronium/Formoterol Fumarate?

Glycopyrronium/Formoterol Fumarate is a LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) drug developed by AstraZeneca, indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Glycopyrronium/Formoterol Fumarate work?

Glycopyrronium is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and improve bronchial tone, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle to improve airflow.

What is Glycopyrronium/Formoterol Fumarate used for?

Glycopyrronium/Formoterol Fumarate is indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Glycopyrronium/Formoterol Fumarate?

Glycopyrronium/Formoterol Fumarate is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Glycopyrronium/Formoterol Fumarate in?

Glycopyrronium/Formoterol Fumarate belongs to the LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) class. See all LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) drugs at /class/lama-laba-combination-long-acting-muscarinic-antagonist-long-acting-beta-2-agonist.

What development phase is Glycopyrronium/Formoterol Fumarate in?

Glycopyrronium/Formoterol Fumarate is in Phase 3.

What are the side effects of Glycopyrronium/Formoterol Fumarate?

Common side effects of Glycopyrronium/Formoterol Fumarate include Tremor, Headache, Palpitations, Dry mouth, Tachycardia, Muscle cramps.

What does Glycopyrronium/Formoterol Fumarate target?

Glycopyrronium/Formoterol Fumarate targets Muscarinic M3 receptor; Beta-2 adrenergic receptor and is a LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist).

Related